FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387680068> ?p ?o ?g. }

• W4387680068 endingPage "504" @default.
• W4387680068 startingPage "504" @default.
• W4387680068 abstract "Objective: We aimed to investigate the association between metabolic syndrome (MetS) and prostate cancer (PCa) in patients undergoing prostate biopsy. Materials and Methods: Between January 2018 and December 2022, MetS was investigated according to Adult Treatment Panel III (ATP III) criteria in men who underwent prostate biopsy with transrectal ultrasound (TRUS). Clinicopathological factors such as, digital rectal examination (DRE), prostate-specific antigen (PSA), prostate volume, waist circumference, body mass index (BMI), age, blood pressure, testosterone, lipid profiles, fasting blood glucose level, C-reactive protein (CRP) and MetS were analyzed. Results: A total of 908 men underwent biopsies, of which 492 (51.5%) had MetS according to ATP III criteria. The number of patients diagnosed with PCa in biopsy was 270 (29.7%). PCa cases were significantly older, with a lower prostate volume and a higher PSA value and higher blood pressure compared to patients without PCa (<i>p</i> < 0.001). 146 of 416 (35.0%) patients with MetS had PCa while 124 of 492 (25.2%) patients without MetS had PCa (<i>p</i> < 0.001). Out of 270 patients with PCa, 174 (64.4%) had Gleason score <7 and 96 (35.6%) had Gleason score ≥7. In patients with a Gleason score ≥7, PSA, DRE(+) and core positive number were significantly higher compared to patients with Gleason score <7, while glycemia and high-density lipoprotein (HDL) cholesterol levels were significantly lower (<i>p</i> < 0.001). Multivariate analysis showed that age, PSA, positive DRE, prostate volume (<i>p</i> < 0.001), diastolic blood pressure, CRP and MetS were the only independent parameters associated with a higher risk of cancer on biopsy (<i>p</i> < 0.05). Conclusions: Our findings show that MetS is associated with PCa diagnosed on biopsy but not with the Gleason score and the number of cancer-positive cores. However, these results should be confirmed by larger, multicenter and prospective studies." @default.
• W4387680068 created "2023-10-17" @default.
• W4387680068 creator A5015330678 @default.
• W4387680068 creator A5024541025 @default.
• W4387680068 creator A5037576947 @default.
• W4387680068 creator A5044031646 @default.
• W4387680068 creator A5053028013 @default.
• W4387680068 date "2023-01-01" @default.
• W4387680068 modified "2023-10-17" @default.
• W4387680068 title "Metabolic Syndrome is Associated with Prostate Cancer Diagnosed on Biopsy but not the Gleason Score and the Number of Cancer-Positive Cores: A Prospective Controlled Study" @default.
• W4387680068 doi "https://doi.org/10.56434/j.arch.esp.urol.20237607.62" @default.
• W4387680068 hasPublicationYear "2023" @default.
• W4387680068 type Work @default.
• W4387680068 citedByCount "0" @default.
• W4387680068 crossrefType "journal-article" @default.
• W4387680068 hasAuthorship W4387680068A5015330678 @default.
• W4387680068 hasAuthorship W4387680068A5024541025 @default.
• W4387680068 hasAuthorship W4387680068A5037576947 @default.
• W4387680068 hasAuthorship W4387680068A5044031646 @default.
• W4387680068 hasAuthorship W4387680068A5053028013 @default.
• W4387680068 hasConcept C121608353 @default.
• W4387680068 hasConcept C126322002 @default.
• W4387680068 hasConcept C126894567 @default.
• W4387680068 hasConcept C2775934546 @default.
• W4387680068 hasConcept C2776193436 @default.
• W4387680068 hasConcept C2776235491 @default.
• W4387680068 hasConcept C2780101318 @default.
• W4387680068 hasConcept C2780192828 @default.
• W4387680068 hasConcept C2780221984 @default.
• W4387680068 hasConcept C2780578515 @default.
• W4387680068 hasConcept C2781217009 @default.
• W4387680068 hasConcept C2781406297 @default.
• W4387680068 hasConcept C511355011 @default.
• W4387680068 hasConcept C71924100 @default.
• W4387680068 hasConcept C84393581 @default.
• W4387680068 hasConceptScore W4387680068C121608353 @default.
• W4387680068 hasConceptScore W4387680068C126322002 @default.
• W4387680068 hasConceptScore W4387680068C126894567 @default.
• W4387680068 hasConceptScore W4387680068C2775934546 @default.
• W4387680068 hasConceptScore W4387680068C2776193436 @default.
• W4387680068 hasConceptScore W4387680068C2776235491 @default.
• W4387680068 hasConceptScore W4387680068C2780101318 @default.
• W4387680068 hasConceptScore W4387680068C2780192828 @default.
• W4387680068 hasConceptScore W4387680068C2780221984 @default.
• W4387680068 hasConceptScore W4387680068C2780578515 @default.
• W4387680068 hasConceptScore W4387680068C2781217009 @default.
• W4387680068 hasConceptScore W4387680068C2781406297 @default.
• W4387680068 hasConceptScore W4387680068C511355011 @default.
• W4387680068 hasConceptScore W4387680068C71924100 @default.
• W4387680068 hasConceptScore W4387680068C84393581 @default.
• W4387680068 hasIssue "7" @default.
• W4387680068 hasLocation W43876800681 @default.
• W4387680068 hasOpenAccess W4387680068 @default.
• W4387680068 hasPrimaryLocation W43876800681 @default.
• W4387680068 hasRelatedWork W1541131697 @default.
• W4387680068 hasRelatedWork W2064191137 @default.
• W4387680068 hasRelatedWork W2131270722 @default.
• W4387680068 hasRelatedWork W2134967293 @default.
• W4387680068 hasRelatedWork W2149157618 @default.
• W4387680068 hasRelatedWork W2347373235 @default.
• W4387680068 hasRelatedWork W3029698927 @default.
• W4387680068 hasRelatedWork W4248685099 @default.
• W4387680068 hasRelatedWork W4313334906 @default.
• W4387680068 hasRelatedWork W2527018723 @default.
• W4387680068 hasVolume "76" @default.
• W4387680068 isParatext "false" @default.
• W4387680068 isRetracted "false" @default.
• W4387680068 workType "article" @default.